Motif Bio Share Discussion Threads

[hazl] 24/9/2015 11:14

Yes seems to have protean!

Interesting htrocka.

[protean] 24/9/2015 10:58

MTFB presenting tonight. Could drum up a few new buyers.

proactiveinvestors.co.uk/register/event_details/40

[protean] 24/9/2015 10:50

Zeus Capital out with 165p target:

[htrocka2] 22/9/2015 17:26

Curiously interesting and possibly a related topic.

[aim_trader] 22/9/2015 09:31

Graham Lumsden, CEO of Motif Bio, will be presenting to investors at the Chesterfield Hotel in Mayfair on the 24th September from 6pm. To register, please click here:

[wh1spa] 10/9/2015 21:02

Tetraphase Pharma, a good example of when things go wrong! I reduced my holding here and bought into AMP. It seemed like a better deal.

[hannahh] 10/9/2015 16:05

If you would like to see Graham Lumsden, CEO, present on behalf of Motif Bio, with the opportunity to ask him questions please follow the link below. The forum will be held on the 23rd of September from 5pm, registration is free.



Also presenting are Stadium Group and Ilika.

Thanks,
The Equity Development Team

[cheshire man] 08/9/2015 10:39

Some decent buys gone through this morning :-)

[regandharry5] 08/9/2015 10:13

80p next resistance.

[singer8] 04/9/2015 10:13

WARNING 21trader PUMP and DUMP

[hazl] 04/9/2015 08:53

Ah THANKS I see

[timbo003] 04/9/2015 08:51

Some broker comment from yesterday:




Also from the proactiveinvestor site:


Proactive Investors One2One Investor Forum - London
EG Solutions | Motif Bio | Amphion Innovations | e-Therapeutics plc
Sep 24th 2015, 6.00 pm - Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair



I will definitely go along to that!

[21trader] 04/9/2015 08:46

Beaufort right at the bottom

[hazl] 04/9/2015 08:38

source MDCHAND?

[mdchand] 04/9/2015 08:17

Motif Bio (MTFB.L, 64.75p) - Speculative Buy

Motif Bio, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, yesterday announced that the US Food and Drug Administration (‘FDA’) has granted Fast Track designation for iclaprim intravenous to treat Acute Bacterial Skin and Skin Structure Infections (‘ABSSSI’;) and Hospital Acquired Bacterial Pneumonia (‘HABP’). The FDA's Fast Track programme is designed to aid the development and accelerate the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Drugs with Fast Track designation typically qualify for priority review, which expedites the FDA review process and market approval. Companies that receive Fast Track designation for a drug benefit from more frequent interactions with the FDA during clinical development and can submit completed sections of their New Drug Application (NDA) on a rolling basis.

Our view: The above development is an important one for Motif. Coming on the back of Qualified Infectious Disease Product (‘QIDP’) designation for iclaprim in late July, Fast Track designation means the company will benefit from greater FDA support and remains on track to meet the Phase III development timeline. A designated development drug benefits from more frequent interactions with the FDA during clinical development and is permitted to submit completed sections of their New Drug Application (‘NDA’) on a rolling basis in order to expedite approval. In approving these novel antibiotic developments, the FDA is recognising the acute clinical need for such new products, while also effectively acknowledging a high expectation of their future commercialisation. The QIDP designation will make iclaprim eligible to benefit from certain incentives as provided under the Generating Antibiotic Incentives Now (‘GAIN’) Act. These incentives include FDA priority review, eligibility for fast-track status, and if ultimately approved by the FDA, iclaprim would be eligible for an additional five-year extension of Hatch-Waxman exclusivity, for a total of 10 years of market exclusivity, starting from the date of NDA approval. Beaufort retains its ‘Speculative Buy’ recommendation on Motif Bio with a price target of 110p per share.

[hitch19] 03/9/2015 13:56

What you think? Coincidence?

[hazl] 03/9/2015 08:38

I see what you mean on the 1st Hitch19.
Are you saying that is a special code between brokers?

[hitch19] 03/9/2015 07:49

Before then. Check the 911 trades just before RNS re US broker

[mdchand] 03/9/2015 07:11

Suspect people knew this announcement was coming yesterday........

[hazl] 02/9/2015 15:07

Thats a bit more like it!

well done MTFB

[regandharry5] 02/9/2015 13:47

Could this be a prelude to dual listing?

[cheshire man] 02/9/2015 07:28

2 September 2015



Motif Bio plc

("Motif" or the "Company")

Motif Appoints Westwicke Partners as Investor Relations Adviser in U.S.



Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has appointed Westwicke Partners as its investor relations adviser in the U.S. Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to public and private companies in the healthcare sector.

Graham Lumsden, CEO of Motif, said: "We look forward to building a relationship with the Westwicke team and to leveraging their experience as we continue to move our clinical development programs forward".



Enquiries

Motif Bio plc

Graham Lumsden (Chief Executive Officer)

Robert Bertoldi (Chief Financial Officer)

www.motifbio.com



[e-mail]





Zeus Capital Limited (NOMINATED ADVISER AND BROKER)

[phone]

Phil Walker/ John Treacy

Dominic Wilson





Northland Capital Partners Limited (BROKER)

[phone]

Patrick Claridge/ David Hignell

John Howes/ Mark Treharne (Broking)





MC Services AG (TRADE PR)

Raimund Gabriel

Shaun Brown







Plumtree Capital Limited (FINANCIAL ADVISOR)



[phone]

[phone]







[phone]

Stephen Austin





Yellow Jersey PR Limited (FINANCIAL PR)

Dominic Barretto

Philip Ranger

Charles Goodwin



[phone]

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.



About Westwicke Partners

Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to healthcare companies. With offices in Baltimore, Boston, San Francisco and San Diego, the firm works with over 80 public and private companies across all subsectors of healthcare. Services provided by Westwicke include corporate messaging and positioning, investor presentation review, sell side relationship building, buy side targeting, earnings call preparation, capital markets advisory, pre-IPO planning and execution, and investor day meetings. All of Westwicke's senior professionals have extensive Wall Street experience as former sell side and buy side research analysts, portfolio managers, investment bankers, institutional sales people, and equity capital markets professionals. The firm works with its clients to help position their story properly within the investment community, raise their visibility on Wall Street, and develop value-added strategies to build a quality, long-term shareholder base and enhance equity market value. For additional information about Westwicke please visit www.westwicke.com.

[regandharry5] 01/9/2015 16:42

Cheeky MMs, tricking people into thinking we were on the way back down, then tick back up near the end of the day.

I wonder how many sellers they tricked with that little ploy.

Buy, tuck away for 6 to 12 months and you will be handsomely rewarded

[aughton 3] 31/8/2015 14:17

@ShareProphets: Just posted: Zak Mir's Bull Call Of The Day No.1: Motif Bio: New Rebound Towards 95p #MTFBhttps://twitter.com/ShareProphets/status/638255588711919616